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Abstract
 
HACS1 is a Src homology 3 and sterile alpha motif domain–containing adaptor that is prefer-
entially expressed in normal hematopoietic tissues and malignancies including myeloid leukemia,
lymphoma, and myeloma. Microarray data showed 
 
HACS1
 
 expression is up-regulated in acti-
vated human B cells treated with interleukin (IL)-4, CD40L, and anti–immunoglobulin (Ig)M
and clustered with genes involved in signaling, including 
 
TNF receptor–associated protein 1
 
,
 
 signaling
lymphocytic activation molecule
 
,
 
 IL-6
 
, and 
 
DEC205
 
. Immunoblot analysis demonstrated that
HACS1 is up-regulated by IL-4, IL-13, anti-IgM, and anti-CD40 in human peripheral blood
B cells. In murine spleen B cells, Hacs1 can also be up-regulated by lipopolysaccharide but not
IL-13. Induction of Hacs1 by IL-4 is dependent on Stat6 signaling and can also be impaired by
inhibitors of phosphatidylinositol 3-kinase, protein kinase C, and nuclear factor 
 
 
 
B. HACS1
associates with tyrosine-phosphorylated proteins after B cell activation and binds in vitro to the
inhibitory molecule paired Ig-like receptor B. Overexpression of HACS1 in murine spleen B
cells resulted in a down-regulation of the activation marker CD23 and enhancement of CD138
expression, IgM secretion, and Xbp-1 expression. Knock down of HACS1 in a human B lym-
phoma cell line by small interfering ribonucleic acid did not significantly change IL-4–stimulated
B cell proliferation. Our study demonstrates that HACS1 is up-regulated by B cell activation
signals and is a participant in B cell activation and differentiation.
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Introduction
 
HACS1 is an adaptor protein identified in our transcrip-
tional study of genes expressed in multiple myeloma (1).
The gene encoding 
 
HACS1
 
 maps to human chromosome
21q11.2, a region frequently disrupted by translocation
events in hematopoietic disorders. Our previous work dem-
onstrated that this gene is highly expressed as a 2.2-kb
transcript in some hematopoietic malignancies including
acute myeloid leukemia, myeloma, and lymphoma, and in
normal bone marrow, lymph node, spleen and thymus.
HACS1 mRNA expression is also observed at a low level
in heart, brain, placenta, and lung. 
 
HACS1
 
 encodes a 441–
amino acid protein containing a Src homology 3 (SH3) do-
main in the middle of the protein and a sterile alpha motif
(SAM) domain at the COOH terminus. It contains three
putative nuclear localization signals, suggesting that it can
be transported to the nucleus. The SH3 motif of the
HACS1 protein shares 39% homology with 
 
CRK
 
, an adap-
tor protein that binds to several tyrosine-phosphorylated
proteins. 
 
HACS1
 
 also shares 50% amino acid homology
with 
 
HACS2/SLY
 
, a highly homologous gene on the X
chromosome (2). In addition, an NH
 
2
 
-terminal splice vari-
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ant, 
 
SAMSN1
 
, encodes a 373–amino acid protein that pre-
serves both the SH3 and SAM domains. Human 
 
HACS1/
SAMSN1
 
 is part of a large segment of chromosome 21
genes conserved on mouse chromosome 16. The ortholo-
gous murine 
 
Hacs1/Samsn1
 
 encodes a highly conserved
protein (87%) of 364 amino acids. A recent study of ex-
pression profiles of mouse orthologs to human chromo-
some 21 genes by a combination of large scale mRNA in
situ hybridization and in silico mining of expressed se-
quence tags (ESTs) suggests that 
 
Hacs1/Samsn1
 
 might be
associated with blood vessel formation during embryogen-
esis (3). Despite this information, the gene regulation and
function of the HACS1 protein remains unknown.
Here, we demonstrate that 
 
HACS1
 
 gene expression is
up-regulated by treatment of B cells with IL-4 and other B
cell activators. By dissecting IL-4 receptor signaling path-
ways, we further demonstrate that up-regulation of 
 
HACS1
 
gene expression by IL-4 requires 
 
STAT6
 
 and activation of
phosphatidylinositol (PI) 3-kinase, protein kinase C (PKC),
and NF-
 
 
 
B. Functional assays further indicate that HACS1
likely mediates its effects in the signaling cascades that regu-
late B cell activation and differentiation.
 
Materials and Methods
 
Cytokines, Antibodies, and Reagents.
 
Cytokines including
hIL-4, mIL-4, mIL-2, mIL-3, mIL-6, mIL-7, mIL-10, hIL-13,
mIL-13, and TNF-
 
 
 
 were from R&D Systems. Anti-CD19 and
anti-B220 microbeads were from Miltenyi Biotec Canada. Anti-
CD40 and goat F(ab
 
 
 
)2 anti–human or mouse IgM were from
Southern Biotechnology Associates, Inc. Anti-HACS1 is a rabbit
polyclonal antibody raised against a glutathione 
 
S
 
-transferase fu-
sion containing the SAM domain and COOH-terminal region
of the human HACS1 protein. The HACS1 antibody recognizes
both mouse and human forms of HACS1 and was used for both
immunoprecipitation and Western blotting. Anti-nPKC
 
  
 
and
anti–pNF-
 
 
 
B p50 were from Santa Cruz Biotechnology, Inc.
Wortmannin and pyrrolidinedithiocarbamate (PDTC) were from
Sigma-Aldrich. Rapamycin (FRAP/mTOR inhibitor), PD98059
(MEK1 inhibitor), anti–phospho-Akt, anti-Akt, anti–phospho-
PKC
 
 
 
, and anti-STAT6 were from Cell Signaling Technology.
Bisindolylmaleimide I (Bis I) and Bay11-7082 were from Cal-
biochem-Novabiochem. The antiphosphotyrosine antibody 4G10
was from Upstate Biotechnology, anti–paired Ig-like receptor B
(PIR-B) polyclonal anti-sera was a gift from Dr. B. Neel (Amer-
ican Red Cross, Bethesda, MD), and anti-HA antibody was
from Roche Diagnostic. HRP-conjugated anti–rabbit or anti–
mouse secondary antibodies and ECL reagent were from Amer-
sham Bioscience. 
 
Stat6 
 
knockout mouse was purchased from
Jackson Laboratory.
 
Bioinformatics.
 
Microarray data from the analysis of diffuse
large B cell lymphoma (4) was chosen primarily because 
 
HACS1
 
was among the genes spotted on the cDNA microarray (NIH
“Lymphochip”). First, the “Lymphochip” was Blast searched
(http://llmpp.nih.gov/lymphoma/search.shtml/) using 
 
HACS1
 
(sequence data available from GenBank/EMBL/DDBJ under
accession no. AF218085) as the query sequence. Alignment re-
sults showed two significant EST hits: IMAGE: 1269200 (se-
quence data available from GenBank/EMBL/DDBJ under ac-
cession no. AA747998) and IMAGE:1356357 (sequence data
available from GenBank/EMBL/DDBJ under accession no.
AA831672). Further analysis was conducted using the Stanford
Online Universal Resource for Clones and ESTs (SOURCE)
(http://source.stanford.edu) retrieval system (5). The SOURCE
database showed cDNA clone IMAGE: 1269200 alone has mi-
croarray data available.
 
B Cell Purification and Stimulation.
 
Human peripheral blood B
cells and murine splenic B cells were selected by magnetic cell
purification using anti-CD19 microbeads and anti-B220 micro-
beads, respectively, to 95% purity, as confirmed by flow cytome-
try analysis. Cells were cultured (2.0 
 
 
 
 10
 
6
 
 cells/ml) in 6-well
plates in RPMI 1640 containing 10% FCS and stimulated with
different cytokines or antibodies. Cytokines added to these cul-
tures included IL-4, IL-2, IL-3, IL-6, IL-7, IL-10, and IL-13 (all
10 ng/ml). Other stimuli were anti-IgM, anti-CD40 (both 5 
 
 
 
g/
ml), and LPS (5 
 
 
 
g/ml). Cells were also pretreated with various
signaling inhibitors (0.1 
 
 
 
M wortmannin; 10 
 
 
 
M PD 98059; 20
nM rapamycin; 5 
 
 
 
m Bis I; 2, 5, and 10 
 
 
 
m Bay11-7082; and 1
and 5 mM PDTC) for 15 min, followed with treatment of 10
ng/ml IL-4 or 5 
 
 
 
g/ml anti-CD40 for 8 h or overnight.
BJAB cells were cultured at 37
 
 
 
C with 5% CO
 
2
 
 in RPMI
1640 supplemented with 10% FBS. For transient transfections,
BJAB cells were electroporated with 20 
 
 
 
g of pEF(HA)
 
2
 
PIR-B
(cytoplasmic tail) in RPMI 1640 using a GENEPulser (Bio-Rad
Laboratories) set at 250 V and 960 
 
 
 
F. Cells were cultured for
24 h, resuspended in 500 
 
 
 
L RPMI 1640 media, prewarmed for
5 min at 37
 
 
 
C, and then stimulated with or without goat anti–
human IgM (Zymed Laboratories) for 5 min. The stimulations
were halted using phosphatase inhibitor buffer (100 mM NaF, 10
mM Na
 
4
 
P
 
2
 
O
 
7
 
, 1 mM Na
 
3
 
VO
 
4
 
, PBS, pH 7.4), collected by cen-
trifugation, and lysed in 0.2% TNE (50 mM Tris, pH 7.5, 150
mM NaCl, 1 mM EDTA, 0.2% NP-40) lysis buffer containing
protease inhibitors and 1 mM Na
 
3
 
VO
 
4
 
.
 
RT-PCR.
 
RT-PCR was performed using standard methods.
The primers used to amplify 
 
HACS1
 
 were: forward, 5
 
 
 
-TAT-
TGACATGGCCACCAAGA-3
 
  
 
and
 
 
 
reverse, 5
 
 
 
-GGCCAATT-
GGAAAATCAGTG-3
 
 
 
; 
 
HACS2/SLY
 
 forward, 5
 
 
 
-TCCAGC-
AGCTTCAAGGATTT-3
 
  
 
and
 
 
 
reverse, 5
 
 
 
-CATCTTGCCCA-
TCTTCCTGT-3
 
 
 
; 
 
Xbp-1
 
 forward, 5
 
 
 
-CCTTGTGGTTGAG-
AACCAGG-3
 
  
 
and reverse, 5
 
 
 
-CTAGAGGCTTGGTGTA-
TAC-3
 
 
 
.
 
Confocal Immunofluorescence Microscopy of B Cells.
 
Primary
splenic murine B cells were treated with or without 10 ng/ml IL-4
for the indicated times and seeded onto glass coverslips that had
been pretreated with 0.01% polyornithine (Sigma-Aldrich). Cov-
erslips were washed twice with PBS plus Ca
 
2
 
 
 
 or Mg
 
2
 
 
 
. Cells
were fixed with 4% paraformaldehyde for 30 min at room tem-
perature and permeabilized with 0.2% Triton X-100 in PBS plus
Ca
 
2
 
 
 
 and Mg
 
2
 
 
 
 for 10 min. After incubation in blocking buffer
(5% BSA in PBS plus Ca
 
2
 
 
 
 and Mg
 
2
 
 
 
), the permeabilized B cells
were incubated with anti-HACS1 antibody (1:1,000) and subse-
quently with Alexa 488–labeled (green fluorescence) anti–rabbit
secondary antibody (1:500) at 37
 
 
 
C for 30 min. Cell nuclei were
stained with propidium iodide (red fluorescence). Coverslips were
mounted with Dako Fluorescent Mounting medium and viewed
with a Leica 4D confocal microscope.
 
Yeast Two-Hybrid and cDNA Library Screening.
 
To identify
binding partners for HACS1, a yeast two-hybrid screen was con-
ducted using the CytoTrap system (Stratagene) which is based on
the reestablishment of the Ras signaling pathway to detect in vivo
protein–protein interactions in the cytoplasm. The full-length
human cDNA of HACS1 was cloned in frame into pSos vector
that was used as the bait. A mouse spleen cDNA library was 
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screened after cotransformation of the bait plasmid and library
into cdc25H yeast. The yeast colonies were selected based on
growth at 37
 
 
 
C from which plasmid DNA was isolated for se-
quence analysis.
 
Generation of Expression Constructs and Retroviruses.
 
The retro-
virus vector miev was originally from Dr. Robert Hawley (Har-
vard Institues of Medicine, Boston, MA). The cDNAs encoding
HACS1 protein were subcloned into this vector followed by se-
quencing. Generation of ecotropic retrovirus was performed as
described (6). Briefly, 10 
 
 
 
g of DNA was used to transfect the
GP
 
 
 
E86 packaging cell line, and after 1 wk of transfection,
EGFP
 
 
 
 cells were sorted using a Coulter Elite cell sorter. The
sorted GP
 
 
 
E86 cells were then expanded and analyzed for
HACS1 expression by Western Blot. Finally, the retroviral super-
natant was harvested from packaging cells.
 
Retroviral Transduction of B Cells and B Cell Activation Analysis.
 
Transduction of splenic B lymphocytes was performed using pu-
rified splenic B220
 
 
 
 cells. Briefly, B220
 
 
 
 cells were stimulated
with 5 
 
 
 
g/ml LPS (Sigma-Aldrich) overnight and cocultured
with viral packaging cells (miev, HACS1/miev) in the presence
of 4 
 
 
 
g/ml polybrene for 2 d. GFP
 
 
 
 B cells were sorted and
counted. 2.5 
 
 
 
 10
 
5
 
 of cells were analyzed by Western blot or
RT-PCR to test expression of HACS1 or Xbp-1 expression. 3 
 
 
 
10
 
4
 
 cells were seeded in triplicate in 96-well plates with or with-
out IL-4 (10 ng/ml) and anti-CD40 (5 
 
 
 
g/ml) for 48 h. Cell
proliferation was measured using an MTT assay (Roche Diagnos-
tic). Cell surface markers (anti-CD23 and anti-CD138) were ana-
lyzed using a FACScalibur flow cytometer (Becton Dickinson)
with CELLQuest software. IgM secretion in the supernatant of
cultured B cells was detected using an ELISA kit according to the
manufacturer’s instruction (BETHYL Laboratories, Inc.).
 
Small Interfering RNA Transduction.
 
Small interfering (si)RNA
duplexes were synthesized and purified by Dharmacon Inc. The
HACS1 target sequence is GGACAGAGCTCATCAAGTGTT.
10
 
6 BJAB cells were transfected with 5  l of 20  M HACS1-
specific siRNA or control scrambled siRNA by electroporation
(Amaxa). 48 h after transfection, an aliquot of cells were har-
vested, treated, and processed for immunoblotting studies. Cells
were seeded at 104 cells/well in triplicate in 96-well plates with
or without anti-IgM (5  g/ml) and IL-4 (25 ng/ml) for 72 h.
Cell proliferation was measured using an MTT assay.
Results
HACS1 Is Expressed in Activated Human B Cells. HACS1
was sequenced from malignant plasma cells and was subse-
quently found to be highly expressed in cell lines from
other human B cell malignancies. Our immunohistochem-
istry analysis of murine lymphoid tissues demonstrated ex-
pression predominantly in the lymph node sinusoids and
splenic red pulp rather than in lymph nodules and splenic
white pulp that contains a more dense mass of lymphocytes
(Fig. 1). Using in silico analysis of microarray data from B
lymphocytes (4), we found that HACS1 gene expression
was low in memory and naïve B cells but had elevated ex-
pression in activated human B cells treated with IL-4,
CD40L, and anti-IgM (Fig. 2, A and B).
Hierarchical cluster analysis (7) of HACS1 demonstrated
it clustering with other genes involved in signaling such as
the TNF receptor–associated protein 1 (TRAF1), signaling
lymphocytic activation molecule (SLAM) precursor, the che-
mokine MIP1 , IL-6, DEC205 (IMAGE clone1337710),
and novel uncharacterized genes such as UniGene cluster
Hs.89104, KIAA0554, and IMAGE clone 684040 (Fig.
2 A). Interestingly, the expression pattern of both HACS1
and DEC205 overlaps suggesting that the function of
HACS1 may be related with that of DEC205. In particular,
we have found HACS1 to be strongly expressed in cul-
tured DCs (not depicted).
To confirm our microarray observations, we performed
gene-specific RT-PCR. Since HACS1 belongs to a novel
gene family of adaptor proteins that includes a highly ho-
mologous gene, HACS2/SLY (1, 2), we looked at the ex-
pression of both genes in splenic B220  B cells. Although
transcripts of both Hacs1 and Hacs2/Sly are present in
mouse B cells, our results indicated that only Hacs1 was in-
duced by IL-4, whereas Hacs2/Sly basal RNA level re-
mained unchanged in the presence of IL-4 (Fig. 2 C).
HACS1 Protein Is Up-Regulated by IL-4 and Other B Cell
Activators in Both Human and Murine Spleen B Cells. To
verify whether our in silico results are consistent at the pro-
Figure 1. Immunohistochemistry of mouse spleen and lymph node. Hacs1 is expressed in mouse splenic red pulp and lymph node sinusoids. Low
power views of spleen (A) and lymph node (B) stained with anti-HACS1. The white pulp (W) and red pulp (R) in spleen are shown in both magnifica-
tions. High power views of spleen and lymph node stained with anti-HACS1 are shown in the bottom panel. Hacs1 is expressed in the cytoplasm of most
of the positive cells but is also present in nuclei of some cells (inset in spleen bottom panel).Up-regulated HACS1 in B Cell Activation 740
tein level, Western analysis was conducted on purified
human peripheral blood CD19  B cells treated with IL-4,
anti-IgM, and anti-CD40. As shown in Fig. 3 A, human
peripheral B cells have a low, basal level expression of
HACS1 protein, but its expression was greatly induced by
IL-4, anti-IgM, or anti-CD40 after overnight treatment.
Since IL-13 receptor (IL-13R) shares the IL-4 receptor
(IL-4R)   chain (8, 9), we next examined the effects of IL-
13 on HACS1 expression. Not surprisingly, HACS1 ex-
pression was also induced by IL-13 in human peripheral B
cells (Fig. 3 B). Accordingly, when we looked at HACS1
expression in four Hodgkin lymphoma (HL) lines, HACS1
expression was detected in three cell lines that express IL-
13 (10, 11) but not in one HL cell line (L540) not express-
ing IL-13 (Fig. 3 B).
The effects of B cell activators on HACS1 expression
were next tested on primary murine splenic B220  B cells.
Similar to human CD19 B cells, a low expression level of
the Hacs1 protein was detected in resting B cells from
mouse spleen but was induced by IL-4 in a dose-dependent
manner (Fig. 4 A). Interestingly, the induced Hacs1 protein
in B220  cells usually appeared as triplet bands, which
might represent protein modifications or alternatively spliced
isoforms. Up-regulation of the Hacs1 protein became ap-
parent after 6 h of treatment as seen on a Western blot of
IL-4–stimulated B220  B cells (Fig. 4 B). These findings
were consistent with the results using confocal immunoflu-
orescence microscopy examining Hacs1 protein in B220 
B cells 6 h after IL-4 stimulation (Fig. 4 C).
Similar to human CD19  B cells, when murine B220 
B cells were treated with other known B cell activators in-
cluding anti-IgM, anti-CD40, and LPS, Hacs1 gene expres-
sion increased, albeit at a lower level for anti-IgM and LPS
stimulation. However, when combined with IL-4, syner-
gistic effects on Hacs1 expression were observed, especially
between IL-4 and anti-CD40 (Fig. 4 D). Other cytokines
including IL-2, IL-3, IL-6, IL-7, IL-10, and IL-13, had no
effect on Hacs1 expression in murine B cells (not depicted),
suggesting that the IL-4 signaling pathway is the dominant
signaling mechanism for Hacs1 expression.
Up-Regulation of HACS1 by IL-4 Is STAT6 Dependent
and Diminished by Inhibition of PI 3-Kinase and PKC. To
dissect the IL-4 signaling pathway which up-regulates
HACS1, three known IL-4 receptor signaling mechanisms,
the Stat6, PI 3-kinase, and Ras/mitogen-activated protein
kinase (MAPK) pathways, were independently investigated.
After IL-4 stimulation of murine splenic B cells, activation
of Stat6 became evident (Fig. 5 A). Similarly, activation of
PI 3-kinase by IL-4 was observed by increased phosphoryla-
tion of Akt, a downstream target of PI 3-kinase (Fig. 5 A).
To determine whether IL-4 regulates Hacs1 levels via Stat6,
we demonstrated the absence of Hacs1 induction in IL-4–
stimulated B220  spleen B cells from a Stat6-deficient mouse
(Fig. 5 B). Thus, Stat6 is absolutely required for Hacs1 induc-
tion by IL-4. By searching for putative transcription factor
binding elements in the 5  putative promoter region of
HACS1, we identified two Stat6 binding elements
(TTCAACAGAA and TTCAATGGAA) at 1.4 and 1.5 kb
upstream of the putative start codon, suggesting that Stat6 can
bind to the HACS1 promoter to exert regulatory function.
Figure 2. In silico analysis of HACS1 expression from microarray hy-
bridization data of lymphocyte samples. (A) HACS1 clustered together
with known signaling proteins and uncharacterized genes and ESTs.
(B) HACS1 can be up-regulated in B cells under different culture condi-
tions such as addition of IL-4, anti-IgM, and CD40L. Data was mined
from Alizadeh et al. (4) through SOURCE (5). (C) Gene-specific RT-PCR
analysis of HACS1 and related gene HACS2/Sly shows only HACS1 can
be up-regulated by IL-4, confirming the microarray data.
Figure 3. HACS1 was up-regulated by IL-4, IL-13, anti-IgM, and
anti-CD40 in human peripheral B cells. (A) Purified human peripheral
CD19  cells were incubated with 10 ng/ml IL-4 or 1  g/ml anti-IgM or
1  g/ml anti-CD40 overnight, and then cells were harvested and lysed
and HACS1 expression was analyzed by Western blot. (B) Western blot
analysis of HACS1 expression in CD19  cells induced by IL-13 (10 ng/ml
overnight) and in human HL cell lines L1236, HDLM2, and L428 and
L540. K562 (erythroleukemia) served as a positive control (1).Zhu et al. 741
To further investigate whether other signaling pathways
activated by IL-4 are also engaged in the up-regulation of
Hacs1, we employed a variety of chemical inhibitors. IL-4
alone was reported not to induce activation of the MAPK
pathway in murine splenic B cells (12, 13). In agreement
with this notion, addition of PD98059, a MAPK inhibitor,
to IL-4–treated spleen B cells did not affect the expression
of Hacs1 (Fig. 5 C), suggesting that Hacs1 regulation does
not go through the Ras/MAPK pathways. In contrast,
when cells were pretreated with a PI 3-kinase inhibitor,
wortmannin, Hacs1 up-regulation was diminished (Fig. 5
C), but addition of rapamycin, an inhibitor of FRAP/
mTOR and p70S6, downstream effectors of PI 3-kinase,
did not affect the up-regulation of Hacs1 by IL-4. These
results suggest that the PI 3-kinase pathway is involved in
IL-4–mediated Hacs1 expression but not via activation of
p70S6 kinase. When cells were pretreated with a pan-PKC
inhibitor Bis1, the up-regulation of Hacs1 by IL-4 was di-
minished but not abolished (Fig. 5 C), implying that up-
regulation of Hacs1 by IL-4 might go through the PI
3-kinase/PKC pathway. Since tyrosine phosphorylation of
Stat6 stimulated by IL-4 was not decreased by either wort-
mannin or Bis I treatment, whereas expression of Hacs1
was significantly reduced, the Stat6 pathway alone cannot
be responsible for IL-4–mediated up-regulation of Hacs1.
Thus, signaling via the PI 3-kinase/PKC pathway and Stat6
pathway appears to play important roles in promoting
Hacs1 expression.
Up-Regulation of HACS1 Involves the NF- B Pathway.
Since activation of PI 3-kinase, in particular the PKC path-
way, is involved in induction of Hacs1 by IL-4, we further
assessed which downstream transcription factors might be
activated and function in this pathway. Activation of PI
3-kinase by IL-4 has been demonstrated to induce different
PKC isoforms including  ,  ,  , and   (14–16). IL-4–acti-
vated PKC  has been shown to enhance germline C 
transcription through activation of NF- B in a human B
lymphoma cell line (15, 17). Recent evidence from PKC 
Figure 4. Hacs1 was up-regulated by IL-4 and other B cell activators in
B220  murine splenocytes. (A) Purified murine B220  splenocytes were
incubated with an increasing amount of IL-4 overnight or (B) incubated
with 10 ng/ml of IL-4 for the indicated time, and then cells were har-
vested, lysed, and analyzed by Western blot. (C) Immunofluorescence
staining of Hacs1 protein in B220  mouse spleen B cells in vitro stimu-
lated with IL-4. The up-regulation of Hacs1 expression (green) was evi-
dent by 6 h poststimulation as shown on the left (green). The nuclei were
stained red with propidium iodide (PPI) as shown on the middle panel. The
right panel shows the two stained images merged together. (D) B220  cells
were incubated with various B cell activators alone or with IL-4 plus dif-
ferent stimuli for the indicated time, and then expression of Hacs1 was
analyzed by Western blot.
Figure 5. Up-regulation of Hacs1 by IL-4 via Stat6, PI 3-kinase, and
PKC pathways. (A) B220  cells were incubated with 10 ng/ml IL-4 for
the indicated time, and the tyrosine phosphorylation of Stat6 and Akt
were analyzed by Western blot. (B) Stat6 is necessary for up-regulation of
Hacs1 by IL-4. B220  cells were purified from Stat6-deficient mice
(Stat6 / ) and control mice (Balb/c and J129) and then incubated with
IL-4 (10 ng/ml) for 18 h. Expression of Hacs1 was analyzed by Western
blot. (C) Inhibition of PI 3-kinase and PKC impaired up-regulation of
Hacs1 by IL-4 in B220  murine splenocytes. B220  cells were pretreated
without or with different inhibitors (100 nM wortmannin [wort], 10  M
PD98059 [PD], 20 nM rapamycin [Rapa], and 5  m Bis I) for 15 min,
and then 10 ng/ml IL-4 were added and incubated for 8 h. The cells were
lysed and analyzed by Western blot.Up-regulated HACS1 in B Cell Activation 742
knockout mice demonstrated that this kinase is important
for NF- B transcriptional activity in both embryonic fibro-
blast and B cells (18). In addition, disruption of the PKC 
locus not only resulted in inhibition of cell proliferation
and survival but also impaired the transcription of NF- B–
dependent genes in B cells (18). To determine whether IL-4–
activated PKC  and up-regulation of Hacs1 by IL-4 is asso-
ciated with nuclear translocation of NF- B in murine
splenic B cells, Western blotting was performed on B220 
cells treated with IL-4 and Bay11-7082, a cell-permeable
chemical inhibitor of NF-kB. As shown in Fig. 6, A and B,
upon IL-4 stimulation PKC  was highly phosphorylated
and the nuclear translocation of NF- B protein p50 was
induced in B220  cells. When B220  cells were pretreated
with Bay11-7082, the IL-4–induced nuclear expression of
NF- B but not Stat6 was abrogated. Treatment of B220 
cells with Bay11-7082 and another NF- B inhibitor
PDTC also resulted in a dose-dependent inhibition of IL-4
and anti-CD40–induced Hacs1 expression (Fig. 6 C), sug-
gesting that Hacs1 expression requires NF- B activity. Sub-
sequent database search and analysis of the HACS1 putative
promoter region revealed a consensus binding sequence for
NF- B at  1.8 kb upstream of the HACS1 start codon.
Association of HACS1 with Tyrosine-phosphorylated Proteins
in Stimulated B Cells. To further investigate the role of
HACS1 in B cell signaling, a human B cell line (BJAB) was
stimulated with or without anti-IgM, and the HACS1-
interacting proteins were examined. Upon stimulation
with anti-IgM, endogenous HACS1 inducibly associated with
multiple tyrosine-phosphorylated proteins, indicating HACS1
may function as an adaptor protein downstream of the B
cell receptor (BCR) (Fig. 7 A).
To identify HACS1 binding proteins important in the
IL-4 signaling pathway, a yeast two-hybrid screen of a
mouse spleen library was conducted. From this screen, 18
clones remained after elimination of false positives. Each
clone contained insert after restriction digest, and every
clone was sequenced. 1 of the 18 clones was identified as
PIR-B, a protein involved in B cell suppression. The PIR-B
fragment obtained from the yeast-two hybrid screen was
386 residues in length and included the transmembrane do-
main and the entire cytoplasmic tail of the receptor (amino
acids 456–841). Therefore, we deemed PIR-B a potential
binding partner of HACS1 in our IL-4 B cell model. PIR-B
Figure 6. IL-4–activated PKC  and up-regulation of Hacs1 was
blocked by inhibition of NF- B. (A) IL-4 induced phosphorylation of
PKC  in murine splenic B cells. B220  cells were incubated with 10 ng/ml
IL-4 for the indicated time, and expression of phosphorylated PKC  was
analyzed by Western blot. (B and C) Inhibition of NF- B blocked nuclear
expression of NF- B and the subsequent up-regulation of Hacs1 by IL-4.
B220  cells were pretreated with or without Bay11-7082 or PDTC for
15 min and then incubated with 10 ng/ml IL-4 for the indicated time.
The nuclear extracts or whole cell lysates were prepared and analyzed for
expression of NF- B p50 and Stat6 in nuclei (B) or for expression of
Hacs1 in whole cells (C) by Western blot.
Figure 7. HACS1 associates with phosphotyrosine-
containing proteins in stimulated B cells. (A) Lysates from
human BJAB cells were immunoprecipitated with anti-
HACS1 antibody and preimmune serum control after
stimulation with or without goat anti–human IgM for 5
min. The presence of tyrosine-phosphorylated proteins asso-
ciated with HACS1 were assessed by immunoblotting with
an antiphosphotyrosine antibody (4G10). Reblotting shows
the level of HACS1 in the BJAB cell line. (B) Human BJAB
cells were electroporated with the cytoplasmic tail of PIR-B
using a pEF(HA)2PIR-B construct or the pEF(HA)2 vector
alone. After stimulation with or without goat anti–human
IgM for 5 min, immunoprecipitation was performed with
anti-HACS1 and control IgG antibodies. Western blotting
was performed with anti-HA antibody (top) and anti-
HACS1 antibody (bottom), showing that the cytoplasmic
tail of PIR-B binds to HACS1 in vitro.Zhu et al. 743
is known to be constitutively tyrosine-phosphorylated in
primary B lymphocytes and negatively regulates the B cell
response (19, 20). Furthermore, IL-4 has been shown to ef-
fect inhibitory receptor expression levels and contribute to
cellular activation. To initially test the HACS1–PIR-B in-
teraction, we conducted in vitro experiments. BJAB cells
were electroporated with a construct containing the cyto-
plasmic tail of PIR-B which was then shown to bind pref-
erentially to endogenous HACS1, suggesting that HACS1
and PIR-B can associate in human B cells under these
experimental conditions (Fig. 7 B). However, association
studies of HACS1 with endogenous PIR-B in primary mu-
rine B cells proved unsuccessful, although HACS1 was
found to constitutively associate with a phosphotyrosine
protein of 110 kD (not depicted).
HACS1 Is Involved in B Cell Activation and Differentiation.
Since HACS1 is up-regulated during B cell activation and
is associated with phosphotyrosyl proteins in stimulated B
cells, its function could be associated with regulating the
cellular response of activated B cells. We investigated
whether HACS1 affects B cell activation and differentia-
tion. Activation of B cells by IL-4 and other B cell activa-
tors usually result in B cell proliferation, cell surface antigen
modification, and differentiation (21). Both IL-4 and anti-
CD40 stimulate the proliferation of B cells and enhance the
expression of cell surface molecules such as the low affinity
Fc receptor for IgE (CD23). When a HACS1 retroviral ex-
pression construct was introduced into murine spleen B
cells, we found that compared with control cells (vector
alone), cell proliferation stimulated by IL-4 and anti-CD40
was inhibited in HACS1-transduced B cells (Fig. 8 A).
Similarly, the expression of CD23 (Fig. 8 B) was impaired
in those cells. In contrast, expression of this exogenous
HACS1 resulted in an enhancement of differentiation of
B220  cells to plasma cells indicated as increased surface
CD138 (syndecan-1) expression, IgM secretion, and up-
regulation of XBP-1 (Fig. 8, C–F).
To further investigate the role of HACS1 in B cells,
HACS1-specific siRNA was electroporated into BJAB
cells, which constitutively express endogenous HACS1.
We found that 48 h after transfection,  90% of endoge-
nous HACS1 had been knocked down in BJAB cells (Fig.
8 G). Compared with control, knock down of HACS1
only marginally affected cell proliferation in both IL-4 and
IgM-treated human B cells (Fig. 8 H).
Discussion
Although our immunohistochemistry analysis of normal
mouse lymphoid tissues did not show predominant expres-
sion of Hacs1 in regions that contain mostly lymphocytes,
in silico mining of published microarray data indicated that
the novel adaptor HACS1 can be up-regulated by IL-4,
anti-IgM, and ligation of CD40 in human B cells. By RT-
PCR and Western blot, we further confirmed induction of
HACS1 by IL-4 and other B cell activators 6 h after treat-
ment, suggesting that HACS1 is a secondary response gene
induced during B cell activation. IL-13, like IL-4, also up-
Figure 8. The role of HACS1 is likely involved in B cell activation and
differentiation. (A) Effects of HACS1 on IL-4 and CD-40–driven B220 
cell proliferation. Murine splenic B220  cells were infected as described in
Materials and Methods. GFP  cells were sorted, and 3   104 cells were
seeded in triplicate in 96-well plates with or without IL-4 (10 ng/ml) or
anti-CD40 (5  g/ml) for 48 h, followed by an MTT assay. The data is rep-
resentative of three independent experiments. (B and C) Effects of HACS1
on the surface phenotype of B220  cells. The cells treated as above in tripli-
cates were harvested and combined and stained with PE-conjugated anti-
bodies against CD23 and CD138. Flow cytometry data is converted to
mean fluorescence intensity of the surface expression of living cells. The data
is representative of three independent experiments. (D) HACS1 enhanced
IgM secretion in vitro. Cell culture supernatant was collected from tripli-
cates of each group above, and IgM levels were measured by ELISA assay.
The mean of triplicates is shown, which is representative of two indepen-
dent experiments. (E) Expression of HACS1 in transduced B220  cells (48 h
postinfection) was confirmed by Western blot analysis. (F) Expression of
Xbp-1 was enhanced in HACS1-transduced B220  cells. Briefly, HACS1
and control virus-infected B220  cells were harvested after 48 h of infec-
tion, and total RNA was extracted, quantitated, and analyzed by RT-PCR.
(G) HACS1-specific siRNA knocked down endogenous HACS1 in BJAB
cells. BJAB cells were transfected with either control scrambled oligos (C) or
HACS1-specific siRNA oligos (H) by electroporation. After 48 h of trans-
fection, cells were treated with indicated reagents for 5 min, and the expres-
sion of HACS1 was analyzed by Western blot. (H) Knock down of HACS1
in BJAB cells did not significantly affect cell proliferation stimulated by IL-4.
48 h after transduction of control (C) and HACS1 (H) siRNA oligos, 1  
104 cells were seeded in triplicate in 96-well plates with or without IL-4 (25
ng/ml) or anti-IgM (5  g/ml) for 72 h, followed by an MTT assay. The
data is representative of two independent experiments.
regulated HACS1 gene expression in human peripheral B
cells. Both IL-4 and IL-13 are Th2-derived pleiotropic cy-
tokines that share common functions in human B cells, in-Up-regulated HACS1 in B Cell Activation 744
cluding modulating surface antigen expression and Ig class
switching (22, 23). The IL-4R  chain is a component of
IL-13 receptors, which includes two surface proteins, IL-
13R 1 and IL-13R 2. Although mouse IL-4 was able to
stimulate Hacs1 gene expression in murine splenic B cells,
mouse IL-13 failed to up-regulate Hacs1 expression. This is
in keeping with the notion that B220  mouse splenocytes
are unresponsive to IL-13 (24) due to the lack of IL-
13R 1 expression (25). IL-2R and IL-7R share a common
subunit (IL-2  chain), which is also shared by IL-4R (14),
but IL-2 and IL-7 did not affect HACS1 gene expression,
indicating that IL-4R  chain–mediated signaling is critical
to  HACS1 induction. Other B cell activators including
anti-IgM, anti-CD40, and LPS also stimulated HACS1
gene expression especially when combined with IL-4, im-
plying that signals mediated by these stimuli must have
some redundancy or interaction with the IL-4 signaling
pathway for the regulation of HACS1.
By dissecting the signaling pathways for the up-regula-
tion of HACS1 by IL-4, we demonstrate that Stat6 is an es-
sential upstream signaling molecule for IL-4–mediated
HACS1 expression. This observation is consistent with the
known role of Stat 6 in IL-4–mediated gene transcription.
Two putative Stat6 binding motif are present within 2 kb
upstream of the HACS1 initiation codon implying that
Stat6 may directly bind to the HACS1 promoter to regu-
late its gene expression. However, studies in Stat6 knock-
out mice demonstrated that Stat6 is necessary for expres-
sion of IL-4–responsive genes (26–28), but Stat6 DNA
binding is not sufficient to activate transcription. Stat6 usu-
ally has been found to cooperate with other transcription
factors, such as NF- B and C-EBP to activate transcription
(29, 30). Recently, Stat6 has been shown physically to in-
teract with NF- B and coactivator p300/CBP. Both of
these transcription factors have been shown to enhance
Stat6-dependent transcriptional activation of IL-4–respon-
sive promoters (31, 32).
Using specific inhibitors, we further demonstrated that
activation of PI 3-kinase is also involved in IL-4–mediated
HACS1 induction in murine splenic B cells. The activation
of PI 3-kinase has been demonstrated to function during B
cell development, growth, and responses (33, 34). In addi-
tion to IL-4, PI 3-kinase can also be activated in BCR,
CD40, and LPS-mediated signal transduction pathways
(35–37). For example, PI 3-kinase can be activated down-
stream of the BCR by antigen or by the ligation of CD40
on B cells. Therefore, the induction of the HACS1 gene
by IL-4, anti-IgM, and anti-CD40 might be explained, at
least partially, by their signaling redundancy upon activa-
tion of PI 3-kinase.
Upon activation by IL-4, PI 3-kinase converts PI 4,5-
bisphosphate into PI 3,4,5-triphosphate that subsequently
activates downstream signaling including serine/threonine
kinase Akt, PKC family or MAPK family, and p70S6 ki-
nase (14). In our study, the activation of PI 3-kinase by IL-4
in murine splenic B cells resulted in the phosphorylation
of Akt, which like HACS1 was diminished when cells were
pretreated with 0.1  m of wortmannin (not depicted).
However, treatment of cells with either p70S6 kinase in-
hibitor or MAPK inhibitor had no effect on HACS1 pro-
tein expression, suggesting that the regulation of HACS1
downstream of PI 3-kinase are not associated with these
pathways. Instead, induction of HACS1 by IL-4 was im-
paired by a PKC inhibitor consistent with the known acti-
vation of PKC as a downstream effector of PI 3-kinase
(38). In our study, we found that PKC , an atypical iso-
form of PKC (aPKC) that is activated by IgM and impli-
cated as a downstream target of PI 3-kinase (18), was activated
by IL-4 stimulation in B220  splenocytes, but antibodies
against phosphorylated conventional PKCs, including PKC ,
 I,  II, and  , failed to detect increasing phosphorylation
of PKC by IL-4 treatment. These observations suggest that
PKC  might be the major isoform activated by IL-4. How-
ever, the involvement of other isoforms of PKC in Hacs1
gene induction cannot be excluded, since IL-4 also has
been found to activate   and PKC  (14, 39). Furthermore,
LPS, which is known for activating various isoforms of
PKC such as  ,  ,  , but not  , also enhanced HACS1
expression.
Both PI 3-kinase and PKC have been demonstrated to
activate NF- B pathways (17, 18, 40, 41). NF- B is associ-
ated with the expression of genes involved in B cell devel-
opment, differentiation, and function (42). Although consti-
tutively active in mature B cells, NF- B is further induced
after stimulation through CD40 or the BCR. In our study,
treatment of B cells with Bay11-7082 and PDTC greatly
impaired synergistic effects of IL-4 and CD40 on Hacs1 ex-
pression, indicating that nuclear expression of NF- B is
critical to Hacs1 induction. In agreement with this observa-
tion, our data mining study indicated that the expression
pattern of IL-4 induced HACS1 clustered together with
characterized NF- B targets such as TRAF1 (43) and IL-6
(44). Consistently, the HACS1 promoter region contains a
putative NF- B binding site (tggcctTTCC) at  1.8kb.
Further study of the role of NF- B using spleen B cells
from an NF- B p50-deficient mouse, however, displayed
normal induction of Hacs1 by IL-4 compared with control
wild-type mouse, thus suggesting that other members of the
NF- B family are responsible for Hacs1 expression. For ex-
ample, a recent study showed that c-Rel is a selective acti-
vator of a novel IL-4/CD40-responsive element that con-
tains overlapping sites for c-Rel and Stat6. This suggests that
IL-4 and CD40 cross-linking regulate the human Ig  4
germline promoter through Stat6/NF- B cooperation (45).
The cooperation between the Stat6 pathway and the NF-
 B may also explain why the combination of IL-4 and anti-
CD40 provides an additive effect on Hacs1 up-regulation.
Our data mining study found that HACS1 clustered to-
gether with SLAM precursor and DEC205. SLAM belongs
to the Ig superfamily of receptors and has been shown
to enhance cellular proliferation, production of inflamma-
tory cytokines, and Ig secretion (46). DEC205 is an en-
docytic receptor with homology to macrophage mannose
receptor that is involved in antigen processing in DCs (47).
DEC205 also interacts with the IL-4R to modulate IL-4R
signal transduction in B cells (48). Interestingly, in additionZhu et al. 745
to the expression of HACS1 in B cells, we found, like
DEC205 and SLAM, that HACS1 is also highly expressed
in DCs, suggesting HACS1 may function as those two
molecules involved in regulating the cellular response of
immune cells.
Peripheral B cell activation is inhibited by a variety of
cell surface receptors including CD22, Fc RII, CD72, and
PIR-B (49). Each of these inhibitory molecules contains
immunoreceptor tyrosine-based inhibitory motifs (ITIMs)
in their cytoplasmic domain. PIR-B has four ITIMs with
the tyrosine in the third ITIM playing a crucial role in me-
diating the inhibitory signal in BCR activation (50). PIR-B
is expressed on the surface of B cells, macrophages, DCs,
and myeloid lineage cells (51). PIR-B associates with the
protein tyrosine kinase Lyn and depends on the protein ty-
rosine phosphatase SHP-1, and possibly SHP-2, to mediate
its inhibitory effect since SHP-1/SHP-2 double-deficient
B cells show a reduction in PIR-B–mediated inhibition
(50). Interestingly, previous work has shown that IL-4 re-
duces the expression of PIR-B at the mRNA and protein
level and this effect is mediated by Stat6 (52). Therefore,
IL-4 abolishes the inhibitory effect of PIR-B and contrib-
utes to B cell activation. A similar effect has been demon-
strated recently in DCs for the inhibitory receptor ILT-2,
the closest human family member to PIR-B, which was
shown to be down-regulated after DC activation (53). Our
yeast two-hybrid and in vitro studies suggested that
HACS1 may associate with PIR-B. Although we were un-
able to demonstrate that the inhibitory receptor PIR-B and
HACS1 associate in a primary B cell model, we cannot ex-
clude the association of these proteins. Probably the bind-
ing of these two proteins is weak and requires a specific as-
say condition or a specific stimulation.
We have also shown that HACS1 interacts with several
inducibly tyrosine-phosphorylated proteins in BJAB cells
(155, 135, 120, 95, 85, 70, 65, and 40 kD) after surface
cross-linking of the BCR. These proteins are additional
potential HACS1 binding partners, and ongoing studies to
identify these proteins will assist in delineating the function
of HACS1 downstream of the BCR.
By introducing a HACS1 expression construct into LPS-
stimulated murine splenic B cells, we found that expression
of this exogenous HACS1 resulted in an enhancement of
differentiation of B220  cells to plasma cells which are
characterized by up-regulation of CD138, IgM secretion,
and expression of Xbp-1. Xbp-1 is the first transcription
factor shown to be selectively and specifically required for
the terminal differentiation of B lymphocytes to plasma
cells (54). Xbp-1–deficient mice possess normal numbers of
activated B lymphocytes and form normal germinal centers,
but they have no plasma cells and secrete very little Ig (54).
IL-4 was discovered recently as the only cytokine to con-
trol Xbp-1 expression in mature B cells through the Stat6
pathway (55). In addition to IL-4, LPS also stimulates Xbp-1
expression and B cell differentiation. Overexpression of
HACS1 appears to enhance the B cell differentiation in-
duced by LPS. We noticed that enhancement of B cell dif-
ferentiation by HACS1 is more remarkable when a lower
dose of LPS (5  g/ml) was used to pretreat B cells. HACS1
alone seems unlikely to be sufficient to induce B cell termi-
nal differentiation since overexpression of HACS1 in BCL-1
cells (which can be differentiated to plasma cells by IL-2
and IL-5 stimulation) failed to up-regulate Xbp-1 and in-
duce IgM secretion (not depicted). These results suggest
that HACS1 may function in a network of pathways that is
required for B cell differentiation. Using siRNA technol-
ogy, we successfully knocked down HACS1 expression in
the K562 (not depicted) and BJAB cell lines. We found
that knock down of HACS1 in the K562 (not depicted)
and BJAB cells did not significantly affect cell proliferation.
In summary, our study demonstrated that HACS1 is up-
regulated upon B cell activation mainly through the IL-4–
mediated signal transduction pathway. Induction of HACS1
by IL-4 involves multiple signaling cascades including acti-
vation of Stat6, PI 3-kinase, PKC kinases, and NF- B, in-
dicating that the function of HACS1 is likely a component
of the signaling cascades leading to B cell activation and
differentiation.
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